Cargando…

A polymorphic repeat in the IGF1 promoter influences the risk of endometrial cancer

Due to the lack of high-throughput genetic assays for tandem repeats, there is a paucity of knowledge about the role they may play in disease. A polymorphic CA repeat in the promoter region of the insulin-like growth factor 1 gene (IGF1 has been studied extensively over the past 10 years for associa...

Descripción completa

Detalles Bibliográficos
Autores principales: Bolton, Katherine A, Avery-Kiejda, Kelly A, Holliday, Elizabeth G, Attia, John, Bowden, Nikola A, Scott, Rodney J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bioscientifica Ltd 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5002956/
https://www.ncbi.nlm.nih.gov/pubmed/27090263
http://dx.doi.org/10.1530/EC-16-0003
_version_ 1782450594459418624
author Bolton, Katherine A
Avery-Kiejda, Kelly A
Holliday, Elizabeth G
Attia, John
Bowden, Nikola A
Scott, Rodney J
author_facet Bolton, Katherine A
Avery-Kiejda, Kelly A
Holliday, Elizabeth G
Attia, John
Bowden, Nikola A
Scott, Rodney J
author_sort Bolton, Katherine A
collection PubMed
description Due to the lack of high-throughput genetic assays for tandem repeats, there is a paucity of knowledge about the role they may play in disease. A polymorphic CA repeat in the promoter region of the insulin-like growth factor 1 gene (IGF1 has been studied extensively over the past 10 years for association with the risk of developing breast cancer, among other cancers, with variable results. The aim of this study was to determine if this CA repeat is associated with the risk of developing breast cancer and endometrial cancer. Using a case–control design, we analysed the length of this CA repeat in a series of breast cancer and endometrial cancer cases and compared this with a control population. Our results showed an association when both alleles were considered in breast and endometrial cancers (P=0.029 and 0.011, respectively), but this did not pass our corrected threshold for significance due to multiple testing. When the allele lengths were analysed categorically against the most common allele length of 19 CA repeats, an association was observed with the risk of endometrial cancer due to a reduction in the number of long alleles (P=0.013). This was confirmed in an analysis of the long alleles separately for endometrial cancer risk (P=0.0012). Our study found no association between the length of this polymorphic CA repeat and breast cancer risk. The significant association observed between the CA repeat length and the risk of developing endometrial cancer has not been previously reported.
format Online
Article
Text
id pubmed-5002956
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Bioscientifica Ltd
record_format MEDLINE/PubMed
spelling pubmed-50029562016-08-30 A polymorphic repeat in the IGF1 promoter influences the risk of endometrial cancer Bolton, Katherine A Avery-Kiejda, Kelly A Holliday, Elizabeth G Attia, John Bowden, Nikola A Scott, Rodney J Endocr Connect Research Due to the lack of high-throughput genetic assays for tandem repeats, there is a paucity of knowledge about the role they may play in disease. A polymorphic CA repeat in the promoter region of the insulin-like growth factor 1 gene (IGF1 has been studied extensively over the past 10 years for association with the risk of developing breast cancer, among other cancers, with variable results. The aim of this study was to determine if this CA repeat is associated with the risk of developing breast cancer and endometrial cancer. Using a case–control design, we analysed the length of this CA repeat in a series of breast cancer and endometrial cancer cases and compared this with a control population. Our results showed an association when both alleles were considered in breast and endometrial cancers (P=0.029 and 0.011, respectively), but this did not pass our corrected threshold for significance due to multiple testing. When the allele lengths were analysed categorically against the most common allele length of 19 CA repeats, an association was observed with the risk of endometrial cancer due to a reduction in the number of long alleles (P=0.013). This was confirmed in an analysis of the long alleles separately for endometrial cancer risk (P=0.0012). Our study found no association between the length of this polymorphic CA repeat and breast cancer risk. The significant association observed between the CA repeat length and the risk of developing endometrial cancer has not been previously reported. Bioscientifica Ltd 2016-05-01 /pmc/articles/PMC5002956/ /pubmed/27090263 http://dx.doi.org/10.1530/EC-16-0003 Text en © 2016 The authors http://creativecommons.org/licenses/by-nc/4.0/ This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Research
Bolton, Katherine A
Avery-Kiejda, Kelly A
Holliday, Elizabeth G
Attia, John
Bowden, Nikola A
Scott, Rodney J
A polymorphic repeat in the IGF1 promoter influences the risk of endometrial cancer
title A polymorphic repeat in the IGF1 promoter influences the risk of endometrial cancer
title_full A polymorphic repeat in the IGF1 promoter influences the risk of endometrial cancer
title_fullStr A polymorphic repeat in the IGF1 promoter influences the risk of endometrial cancer
title_full_unstemmed A polymorphic repeat in the IGF1 promoter influences the risk of endometrial cancer
title_short A polymorphic repeat in the IGF1 promoter influences the risk of endometrial cancer
title_sort polymorphic repeat in the igf1 promoter influences the risk of endometrial cancer
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5002956/
https://www.ncbi.nlm.nih.gov/pubmed/27090263
http://dx.doi.org/10.1530/EC-16-0003
work_keys_str_mv AT boltonkatherinea apolymorphicrepeatintheigf1promoterinfluencestheriskofendometrialcancer
AT averykiejdakellya apolymorphicrepeatintheigf1promoterinfluencestheriskofendometrialcancer
AT hollidayelizabethg apolymorphicrepeatintheigf1promoterinfluencestheriskofendometrialcancer
AT attiajohn apolymorphicrepeatintheigf1promoterinfluencestheriskofendometrialcancer
AT bowdennikolaa apolymorphicrepeatintheigf1promoterinfluencestheriskofendometrialcancer
AT scottrodneyj apolymorphicrepeatintheigf1promoterinfluencestheriskofendometrialcancer
AT boltonkatherinea polymorphicrepeatintheigf1promoterinfluencestheriskofendometrialcancer
AT averykiejdakellya polymorphicrepeatintheigf1promoterinfluencestheriskofendometrialcancer
AT hollidayelizabethg polymorphicrepeatintheigf1promoterinfluencestheriskofendometrialcancer
AT attiajohn polymorphicrepeatintheigf1promoterinfluencestheriskofendometrialcancer
AT bowdennikolaa polymorphicrepeatintheigf1promoterinfluencestheriskofendometrialcancer
AT scottrodneyj polymorphicrepeatintheigf1promoterinfluencestheriskofendometrialcancer